TABLE 2.
Characteristics of α1‐adrenoceptor antagonist users by type of exposure before lag time (exposure at least 3 years before the index date), including individuals with and without AD
| No use N = 87 546 | Only alfuzosin use N = 3869 | Only tamsulosin use N = 27 717 | Purchases of both alfuzosin and tamsulosin N = 3867 | |
|---|---|---|---|---|
| Age at index date mean, (95% CI) | 78.1 (64.4–88.9) | 79.6 (68.8–89.3) | 80.4 (70.3–89.4) | 80.5 (70.3–89.4) |
| Age at first α1‐adrenoceptor antagonist purchase, mean, (95% CI) | 73.2 (73.0–73.4) | 72.1 (72.0–72.29) | 71.0 (70.8–71.2) | |
| Highest occupational class before AD, n, (%) | ||||
| Managerial/professional | 23 132 (26.4) | 1148 (29.7) | 7831 (28.3) | 1257 (32.5) |
| Office | 2605 (3.0) | 111 (2.9) | 773 (2.8) | 111 (2.9) |
| Farming, forestry | 19 843 (22.7) | 857 (22.2) | 6647 (24.0) | 809 (20.9) |
| Sales, industrial, cleaning | 37 455 (42.8) | 1687 (43.6) | 11 848 (42.8) | 1613 (41.7) |
| Unknown | 4511 (5.2) | 66 (1.7) | 618 (2.2) | 77 (2.0) |
| Cardiovascular disease, n, (%) | 38 792 (44.3) | 1867 (48.3) | 14 679 (53.0) | 2051 (53.0) |
| Stroke, n, (%) | 6627 (7.6) | 342 (8.8) | 2923 (10.6) | 458 (11.8) |
| Diabetes, n, (%) | 8747 (10.0) | 449 (11.6) | 3335 (12.0) | 468 (12.1) |
| Asthma/COPD, i, (%) | 7034 (8.0) | 401 (10.4) | 3287 (11.9) | 473 (12.2) |
| Cataract, n, (%) | 11 734 (13.4) | 722 (18.7) | 5346 (19.3) | 837 (21.6) |
| Acute cancer, n, (%) | 6168 (7.1) | 393 (10.2) | 3308 (11.9) | 445 (11.5) |
| Inpatient care with psychiatric diagnoses, n, (%) | 3648 (4.2) | 204 (5.3) | 1455 (5.3) | 233 (6.0) |
| Substance abuse, n, (%) | 4902 (5.6) | 232 (6.0) | 1827 (6.6) | 284 (7.34) |
| Benzodiazepine & related drug use, n, (%) | 19 961 (22.8) | 1314 (34.0) | 10 415 (37.6) | 1726 (44.6) |
| Antidepressant use, n, (%) | 9743 (11.1) | 690 (17.8) | 5234 (18.9) | 994 (25.7) |
| Antipsychotic use, n, (%) | 3300 (3.8) | 185 (4.8) | 1556 (5.6) | 271 (7.0) |
| 5‐ARI drug use, n, (%) | 1279 (1.5) | 104 (2.7) | 1212 (4.4) | 218 (5.6) |
| Sum of purchased ATC‐codes a , median (IQR) | 1 (0–4) | 2 (0–5) | 3 (1–5) | 3 (1–6) |
| Categorized drug sum a , n, (%) | ||||
| None | 32 056 (36.3) | 1053 (27.2) | 6122 (22.1) | 717 (18.5) |
| 1–2 | 23 702 (27.1) | 1027 (26.5) | 7291 (26.3) | 951 (24.6) |
| 3–4 | 15 667 (17.9) | 810 (20.9) | 5942 (21.4) | 796 (20.6) |
| 5–7 | 10 908 (12.5) | 624 (16.1) | 5048 (18.2) | 798 (20.6) |
| 8 or more | 5213 (6.0) | 355 (9.2) | 3314 (12.0) | 605 (15.7) |
| Hospital admissions during lag time, n, (%) | ||||
| 0 | 42 246 (48.3) | 1494 (38.6) | 9853 (35.6) | 1202 (31.1) |
| 1 | 16 550 (18.9) | 808 (20.9) | 5539 (20.0) | 764 (19.8) |
| 2 | 10 060 (11.5) | 513 (13.3) | 3771 (13.6) | 560 (14.5) |
| 3 | 6025 (6.9) | 338 (8.7) | 2477 (8.9) | 384 (9.9) |
| 4–5 | 6430 (7.3) | 354 (9.2) | 2.849 (10.3) | 424 (11.0) |
| 6 or more | 6235 (7.1) | 362 (9.4) | 3228 (11.7) | 533 (13.8) |
| Outpatient visits during lag time, n, (%) | ||||
| 0 | 26 483 (30.3) | 669 (17.3) | 4654 (16.8) | 453 (11.7) |
| 1–2 | 18 096 (20.7) | 747 (19.3) | 5278 (19.0) | 644 (16.7) |
| 3–4 | 12 685 (14.5) | 610 (15.8) | 4306 (15.5) | 542 (14.0) |
| 5–6 | 8439 (9.6) | 480 (12.4) | 3421 (12.3) | 475 (12.3) |
| 7–11 | 11 642 (13.3) | 707 (18.3) | 5075 (18.3) | 793 (20.5) |
| 12 or more | 10 201 (11.7) | 656 (17.0) | 4983 (18.0) | 960 (24.8) |
| New drugs b during lag time, n, (%) | ||||
| 0 | 13 727 (15.7) | 224 (5.8) | 1581 (5.7) | 137 (3.5) |
| 1 | 10 862 (12.4) | 365 (9.4) | 2543 (9.2) | 226 (5.8) |
| 2–3 | 21 711 (24.8) | 896 (23.2) | 6161 (22.2) | 727 (18.8) |
| 4–6 | 22 346 (25.5) | 1188 (30.7) | 8321 (30.0) | 1121 (29.0) |
| 7 or more | 18 900 (21.6) | 1196 (30.9) | 9111 (32.9) | 1656 (42.8) |
a
In year 1995.
b
Excluding α1‐adrenoceptor antagonists.